In animal models, the experimental compound IkT-148009, an inhibitor of Abelson’s tyrosine kinase (c-Abl), prevented the accumulation of the misfolded protein α-synuclein, which is associated with Parkinson’s disease (PD). Treatment with the inhibitor prevented neurodegeneration. Read More
A noninvasive method for administering monoclonal antibodies reliably and reproducibly to central nervous system (CNS) targets remains a significant unmet need. Researchers in Switzerland have reported making headway in bypassing the blood-brain barrier through the intranasal delivery of full-length antibodies in rodent models. They show this delivery route leads to rapid transfer of significant amounts of a mouse antibody targeted against Nogo-A, a membrane protein that inhibits growth of neurites in the brain and spinal cord. Read More
Researchers from National Cheng Kung University and Taipei Medical University reported the discovery and biological evaluation of novel activating transcription factor 3 (ATF3) inducers as potential candidates for the management of metabolic syndrome. Read More
Exegenesis Bio (Hangzhou Exegenesis Biotechnology Co. Ltd.) has received FDA clearance of its IND application for EXG-102-031, a recombinant adeno-associated virus (rAAV)-based gene therapy that is being studied for the treatment of neovascular age-related macular degeneration (AMD). Read More
Chemokine-like receptor 1 (CMKLR1) is a G protein-coupled receptor for chemerin and resolvin E1 that plays a key role in the recruitment and activation of macrophages, natural killer cells and plasmacytoid dendritic cells in inflammatory diseases. Read More
During metastasis, the mechanical properties of the nucleus make translocation of this organelle the rate-limiting step during constrained migration, and these properties are regulated through interactions between the cytoskeleton, integral nuclear envelope (NE) proteins, the nuclear lamina and chromatin. Read More
Reservoir Neuroscience Inc. has disclosed prostaglandin E2 receptor EP2 subtype (PTGER2; EP2) antagonists reported to be useful for the treatment of inflammation. Read More
Harbour Biomed Ltd. has received FDA clearance of its IND application to initiate clinical trials in the U.S. with HBM-1007, a fully human monoclonal antibody targeting CD73. Read More
Abbvie Inc. has described new proteolysis targeting chimera (PROTA) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to tyrosine protein phosphatase nonreceptor type 2 (PTPN2)-targeting moiety reported to be useful for the treatment of cancer, diabetes type 2 and nonalcoholic steatohepatitis. Read More
Blueprint Medicines Corp. has presented epidermal growth factor receptor (EGFR) (mutant) inhibitors reported to be useful for the treatment of cancer. Read More
C4x Discovery Holdings plc has advanced its MALT-1 inhibitor program into the preclinical candidate selection phase. Inhibition of MALT-1 has potential therapeutic applicability as a monotherapy for MALT-1-driven cancers and in combination with BTK inhibitors across multiple hematological indications, as well as broader potential in solid tumors and inflammation. Read More
Sitryx Therapeutics Ltd. has identified nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders. Read More
